ES2196501T3 - Utilizacion de aminoacidos marcados con c13 como agente de diagnostico en la diabetes. - Google Patents

Utilizacion de aminoacidos marcados con c13 como agente de diagnostico en la diabetes.

Info

Publication number
ES2196501T3
ES2196501T3 ES98308523T ES98308523T ES2196501T3 ES 2196501 T3 ES2196501 T3 ES 2196501T3 ES 98308523 T ES98308523 T ES 98308523T ES 98308523 T ES98308523 T ES 98308523T ES 2196501 T3 ES2196501 T3 ES 2196501T3
Authority
ES
Spain
Prior art keywords
labeled
specific position
group
diabetes
diagnostic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98308523T
Other languages
English (en)
Inventor
Tadashi Kohno
Isaburo Hosoi
Junko Ohshima
Asuka Ito
Kunihiko Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Gas Co Ltd
Original Assignee
Tokyo Gas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP28862997A external-priority patent/JP4007654B2/ja
Priority claimed from JP28852697A external-priority patent/JP4007653B2/ja
Priority claimed from JP9313077A external-priority patent/JPH11147842A/ja
Priority claimed from JP34115497A external-priority patent/JP4007659B2/ja
Priority claimed from JP00641098A external-priority patent/JP4007663B2/ja
Priority claimed from JP02461498A external-priority patent/JP4007668B2/ja
Priority claimed from JP02461398A external-priority patent/JP4007667B2/ja
Application filed by Tokyo Gas Co Ltd filed Critical Tokyo Gas Co Ltd
Application granted granted Critical
Publication of ES2196501T3 publication Critical patent/ES2196501T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Atmospheric Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE RELACIONA CON UN AGENTE DIAGNOSTICO PARA LA DIABETES QUE CONSTA DE UNA COMPOSICION ETIQUETADA CON SUP,13 C EN AL MENOS UNA POSICION ESPECIFICA SELECCIONADA A PARTIR DE UN GRUPO CONSISTENTE EN: (A) GALACTOSA, FRUCTOSA O XILOSA ETIQUETADA CON 13 C EN AL MENOS UNA POSICION ESPECIFICA, O UN ALMIDON COMPUESTO POR UNIDADES DE GLUCOSA ETIQUETADAS CON 13 C EN AL MENOS UNA POSICION ESPECIFICA; (B) UN AMINOACIDO ETIQUETADO CON 13 C EN AL MENOS UNA POSICION ESPECIFIC A; (C) ACIDO LACTICO O CITRICO ETIQUETADO CON 13 C EN AL MENOS UNA POSICION ESPECIFICA; (D) UN ACIDO GRASO ETIQUETADO CON 13 C EN AL MENOS UNA POSICION ESPECIFICA; (E) UN GLICE RIDO ETIQUETADO CON 13 C EN AL MENOS UNA POSICION ESPECIFICA; (F) GLICEROL ETIQUETADO CON 13 C EN AL MENOS UNA POS ICION ESPECIFICA; (G) AMINOPIRINA CUYO GRUPO DE DIMETILAMINO EN LA POSICION 4 ESTA ETIQUETADO CON 13 C, FENACETINA CUYO GRUPO DE ETOXI ESTA ETIQUETADO CON 13 C EN LA POSICION 1 O METACETINA CUYO GRUPO DE METOXI ESTA ETIQUETADO CON 13C.
ES98308523T 1997-10-21 1998-10-19 Utilizacion de aminoacidos marcados con c13 como agente de diagnostico en la diabetes. Expired - Lifetime ES2196501T3 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP28862997A JP4007654B2 (ja) 1997-10-21 1997-10-21 糖尿病診断剤
JP28852697A JP4007653B2 (ja) 1997-10-21 1997-10-21 糖尿病診断剤
JP31376397 1997-11-14
JP9313077A JPH11147842A (ja) 1997-11-14 1997-11-14 糖尿病診断剤
JP32080597 1997-11-21
JP34115497A JP4007659B2 (ja) 1997-12-11 1997-12-11 糖尿病診断剤
JP00641098A JP4007663B2 (ja) 1998-01-16 1998-01-16 糖尿病診断剤
JP02461498A JP4007668B2 (ja) 1997-11-14 1998-02-05 糖尿病診断剤
JP02461398A JP4007667B2 (ja) 1997-11-21 1998-02-05 糖尿病診断剤

Publications (1)

Publication Number Publication Date
ES2196501T3 true ES2196501T3 (es) 2003-12-16

Family

ID=27576523

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98308523T Expired - Lifetime ES2196501T3 (es) 1997-10-21 1998-10-19 Utilizacion de aminoacidos marcados con c13 como agente de diagnostico en la diabetes.
ES03000243T Expired - Lifetime ES2304472T3 (es) 1997-10-21 1998-10-19 Agente de diagnostico para la diabetes que comprende un compuesto marcado con 13c.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03000243T Expired - Lifetime ES2304472T3 (es) 1997-10-21 1998-10-19 Agente de diagnostico para la diabetes que comprende un compuesto marcado con 13c.

Country Status (5)

Country Link
US (1) US6509002B1 (es)
EP (2) EP0913161B1 (es)
CA (1) CA2250485C (es)
DE (2) DE69839314T2 (es)
ES (2) ES2196501T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461870B2 (en) 1998-05-06 2002-10-08 Isotechnika Inc. 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
US6468802B1 (en) 1998-05-06 2002-10-22 Isotechnika, Inc. 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
MXPA02010852A (es) * 2000-05-02 2003-07-14 Otsuka Pharma Co Ltd Preparacion para medir la habilidad de vaciado gastrico.
ITMI20010885A1 (it) * 2001-04-27 2002-10-27 Eurospital S P A Metodo per la determinazione di neoplasie gastriche ed esofagee
EP2821788A1 (de) * 2005-06-25 2015-01-07 Freie Universität Berlin Analyseverfahren zur Bestimmung eines Organfunktionsparameters
CA2616788C (en) * 2005-07-25 2014-01-07 Otsuka Pharmaceutical Co., Ltd. Oral preparation useful in measuring capacity to metabolize pyridine
US8512258B2 (en) 2005-11-11 2013-08-20 Exalenz Bioscience Ltd. Breath test device and method
EP1960004A4 (en) * 2005-11-11 2011-04-20 Breathid 2006 BREATHING TEST AND METHOD
KR101440980B1 (ko) * 2006-04-13 2014-09-17 오츠카 세이야쿠 가부시키가이샤 디스펩시아 진단 검사약
CA2882528A1 (en) 2012-08-20 2014-02-27 Otsuka Pharmaceutical Co., Ltd. Method for measuring carbohydrate metabolism ability, and composition for use in said method
US10000787B2 (en) * 2012-10-10 2018-06-19 Stc.Unm Methods for diagnosing bacterial infections
EP2975400B1 (en) * 2013-03-15 2019-09-04 Otsuka Pharmaceutical Co., Ltd. Composition for use in a method for measuring sugar/fatty acid combustion ratio
JPWO2018097222A1 (ja) * 2016-11-25 2019-10-17 大塚製薬株式会社 栄養状態の評価方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298347A (en) * 1980-02-25 1981-11-03 Kor Incorporated 13 CO2 Breath test
US5164308A (en) * 1990-05-21 1992-11-17 Martek Corporation Preparation of labelled triglyceride oils by cultivation of microorganisms
US5413917A (en) * 1990-07-18 1995-05-09 Board Of Regents, The University Of Texas System Method of determining sources of acetyl-CoA under nonsteady-state conditions
US5227296A (en) * 1990-09-25 1993-07-13 Board Of Regents, The University Of Texas System Enzymatic synthesis of isotopically labeled carbohydrates, nucleotides and citric acid intermediates
IL101120A (en) * 1991-03-08 1996-10-31 Tokyo Gas Co Ltd Preparation of compounds marked C31
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
EP0826377B1 (en) * 1996-08-27 2002-11-06 Tokyo Gas Co., Ltd. Diagnostic agent for diabetes
JP3340391B2 (ja) * 1997-09-11 2002-11-05 東京瓦斯株式会社 肝手術評価用試薬
CA2249173C (en) * 1997-10-06 2008-12-16 Tokyo Gas Co., Ltd. Diagnostic agent for liver function
US6468802B1 (en) * 1998-05-06 2002-10-22 Isotechnika, Inc. 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control

Also Published As

Publication number Publication date
DE69839314T2 (de) 2009-04-09
CA2250485C (en) 2008-04-29
EP1304124B1 (en) 2008-03-26
US6509002B1 (en) 2003-01-21
EP0913161A2 (en) 1999-05-06
CA2250485A1 (en) 1999-04-21
DE69812532T2 (de) 2003-12-18
DE69812532D1 (de) 2003-04-30
ES2304472T3 (es) 2008-10-16
EP0913161A3 (en) 2000-08-30
EP1304124A1 (en) 2003-04-23
EP0913161B1 (en) 2003-03-26
DE69839314D1 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
ES2196501T3 (es) Utilizacion de aminoacidos marcados con c13 como agente de diagnostico en la diabetes.
BR0110393A (pt) Composição em barra, método para a limpeza da pele, e, processo para a produção de uma composição em barra.
CY2008009I2 (el) 6.αλφα., 9.αλφα. - διφθορο-17.αλφα.-(2-φουρανυλοανθρακοξυλικο) οξυ-11.βητα.-υδροξυ-16.αλφα.-μεθυλο-3-οξο-ανδροστα-1,4-διενιο-17-ανθρακοθειικο οξυ s-φθορομεθυλο εστερας ως αντιφλεγμονωδης παραγοντας
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
BR0012212A (pt) Processo de hidrogenação de 3-hidroxipropanal em 1,3-propanodiol, processo de preparação de 1,3-propanodiol, processo de purificação de uma solução aquosa de 3-hidroxipropanal e composição de 1,3-propanodiol
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
KR910004199A (ko) 수성 이고제형 제약 조성물
EA199801001A1 (ru) Состав для очистки кожи, способы его приготовления и использования
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
BR0009340B1 (pt) composiÇço adequada para uso na pele ou no cabelo, produto para aplicaÇço na pele ou no cabelo, mÉtodo para preparar uma composiÇço adequada para aplicaÇço na pele ou no cabelo, e, uso de uma composiÇço.
AR022358A1 (es) Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
BR9913589A (pt) Composição, e, processo cosmético para reduzir ardência ou irritação induzidas pela aplicação tópica de uma composição
ES2159919T3 (es) Procedimiento para la preparacion de compuestos de tipo ceramidas.
DE58905235D1 (de) Wasch- und reinigungsmittel.
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
DK0416677T3 (da) Præparater til topisk anvendelse indeholdende depolymeriserede nukleinsyrer
BRPI0418070A (pt) composição para cuidados pessoais, uso de uma uréia substituìda e método para reduzir a degradação da cor de uma composição para cuidados pessoais
PT1023034E (pt) Formulacoes cosmeticas para prevencao e tratamento da queda de cabelo
GB2349336B (en) Pesticidal composition based on 2-methoxycarbonyl-4-chlorotrifluoromethanesulphonanilide & an ester of an alkanedicarboxylic, citric or fatty acid
BR0015060A (pt) Agentes para promover engorda de animais e método para promover engorda
DK0938584T3 (da) Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre
ES2184150T3 (es) Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas.
BR9804026A (pt) Processo para produção de produtos da degradação de ácidos graxos.